Prosecution Insights
Last updated: November 04, 2026

Tiffani C. Chance

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Tiffani C. Chance has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit. The current patent activity is concentrated on a single biotechnological matter. This focused approach allows for a dedicated prosecution strategy that addresses the specific technical requirements of the 1 distinct art unit involved.

WESTON, ALYSSA G is the busiest examiner for the portfolio, managing 1 pending office action. This single matter constitutes the entire pending workload for the company. The prosecution timeline will be determined by the specific caseload and requirements of this 1 examiner. Practitioners should tailor their legal arguments to the specific examination style of WESTON, ALYSSA G to advance the application.

With only 1 pending office action, the company does not have to manage multiple examiners or art units. However, this also means that the company's entire active patent presence is dependent on the outcome of this single matter. Practitioners should carefully review the standards of the Biotechnology & Pharmaceuticals technology area to ensure that the application is positioned for a favorable review by the 1 distinct examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WESTON, ALYSSA G 1 59.2% +50.7%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18037478 EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS WESTON, ALYSSA G 7d

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18037478 EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS WESTON, ALYSSA G 7d

Top Art Units

Art UnitApps
1633 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18037478 EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS WESTON, ALYSSA G 1633 §102§103 Final Rejection 7d Pending Nov 12, 2023

Managing Tiffani C. Chance's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Tiffani C. Chance have?

Tiffani C. Chance has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Tiffani C. Chance applications?

Alyssa G Weston has the most, with 1 of Tiffani C. Chance's pending office actions.

What technology area are Tiffani C. Chance's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month